Table 2.

Synovial expression of CD markers and cytokines before and after treatment with infliximab

	Week 0	Week 9	P
CD3a	2 (0–3)	2 (0–2.5)	Ns
CD68a	2.5 (1–3)	1 (0–2)	0.02
CD163a	1.5 (0–3)	1.5 (0–2)	Ns
TNF mAb1 and mAb11a	0 (0–1)	0 (0–1)	Ns
TNF 2C8b	0.25 (0–5.5)	0.3 (0–17.4)	Ns
IFN-γa	1 (0–2)	0 (0–2)	Ns
IL-1αb	0.9 (0.1–4.9)	1.2 (0.1–3.7)	Ns
IL-1ßb	0.6 (0.1–7.3)	0.8 (0–33.1)	Ns
IL-15 neutralizingb	2.7 (0.1–11.3)	2.8 (0–6.6)	Ns
IL-15 non-neutralizingb	3.6 (0.4–16.7)	7.5 (0–15.1)	Ns

Synovial expression of CD markers (CD3 (T cells), CD68 (macrophages) and CD163 (fibroblasts)) and cytokines (IL-1a, IL-1ß, IL-15 neutralizing antibody, IL-15 non-neutralizing antibody, tumour necrosis factor (TNF; mAb1 and mAb11) and IFN-γ) was measured before treatment and after a median of 9 weeks of treatment with infliximab in patients with rheumatoid arthritis. ^aA semi-quantitative analysis was performed for the CD markers CD3, CD68 and CD163. Values are medians of the score for numbers of positive stained cells with ranges in parenthesis; a semi-quantitative four-point scale was used: 0 = no infiltration, 1 = minimal infiltration, 2 = moderate infiltration and 3 = marked infiltration. A semi-quantitative analysis of cytokines, TNF (mAb1 and mAb11) and IFN-γ was also performed. Values are medians of the score for numbers of positive stained cells, with ranges in parenthesis; a semi-quantitative four-point scale was used: 0 = no positive cells, 1 = 1 to 10 positive cells, 2 = 11 to 100 positive cells, and 3 = more than 100 positive cells. ^bA computerized image analysis was performed for IL-1α, IL-1ß, IL-15 neutralizing antibody and IL-15 non-neutralizing antibody; values are median percentages of the stained tissue area, with ranges in parenthesis. ns, not significant.